Bern Murray M
The Cancer Center of Boston, Boston, MA 02120, USA.
Hematology. 2005 Feb;10(1):65-8. doi: 10.1080/10245330410001701594.
Cancer of the prostate can be associated with coagulopathy characterized as primary fibrinolysis or diffuse intravascular coagulopathy (DIC) with secondary fibrinolysis. These complications are usually associated with surgical manipulation of the prostate or with advanced metastatic disease. This report describes a patient with DIC and fibrinolysis following medical management of advanced prostate cancer with gonadotropin-releasing hormone leuprolide, while receiving the androgen receptor blocking agent flutamide. This report suggests that release of procoagulant material from prostatic carcinoma may be so rapid following hormonal management that consumptive coagulopathy with fibrinolysis can follow. Shortened Abstract: Medical management with gonadotropin releasing hormone allowed the expression of consumptive coagulopathy in patients with metastatic prostate cancer.
前列腺癌可能与以原发性纤维蛋白溶解或伴有继发性纤维蛋白溶解的弥漫性血管内凝血(DIC)为特征的凝血病相关。这些并发症通常与前列腺手术操作或晚期转移性疾病有关。本报告描述了一名晚期前列腺癌患者在接受促性腺激素释放激素亮丙瑞林药物治疗,同时服用雄激素受体阻断剂氟他胺后发生DIC和纤维蛋白溶解的情况。本报告提示,激素治疗后前列腺癌促凝物质的释放可能非常迅速,以至于随后可能发生伴有纤维蛋白溶解的消耗性凝血病。简短摘要:促性腺激素释放激素的药物治疗使转移性前列腺癌患者出现消耗性凝血病。